Curis, Inc. (CRIS) - 500 Beiträge pro Seite

[benefactor [KommA]]

Company Information

Curis, Inc.. The Group`s principal activities are discovery of drug targets and the development of therapeutics. This field seeks to improve, restore or preserve the normal function of tissues and organs by harnessing the body`s inherent ability to repair damage caused by disease, trauma or age. The Group uses its functional genomics and developmental biology expertise to activate cellular development pathways to promote repair and normal tissue and organ function. This can be also used to inhibit abnormal growth pathways to treat certain types of cancer. License fees and royalties accounted for 99% of 2002 revenues and research and development contracts, 1%.

http://www.curis.com/

Cash Per Share ($) 1.15

Revenues (Units in Thousands of U.S. Dollars $)

Quarter 2001 2002

Q1 249 159
Q2 203 190
Q3 288 223
Q4 347 17819

Earnings Per Share (Units in U.S. Dollars $)

Quarter 2001 2002

Q1 -0.57 -0.56
Q2 -0.61 -2.20
Q3 -0.89 -0.18
Q4 -0.51 0.35

[benefactor [KommA]]

[doobie.de]

wasn damit?

[benefactor [KommA]]

Wenn Curis (CRIS) die Revenues (Q 4) auf diesem Niveau halten kann, haben wir es mit einer Topstock zu tun.

[benefactor [KommA]]

[benefactor [KommA]]

1.70$

[benefactor [KommA]]

CURIS Issued U.S. Patent on Small Molecule Inhibitors of Hedgehog Pathway

Claims Cover Cur-61414, a Drug Candidate under Development for Basal Cell Carcinoma

CAMBRIDGE, Mass., Apr 23, 2003 (BUSINESS WIRE) -- CURIS, Inc. (NASDAQ:CRIS) - The U.S. Patent and Trademark Office yesterday issued Patent 6,552,016 to Curis covering pharmaceutical preparations containing small molecule compounds that selectively inhibit a biological signaling pathway controlled by a protein called Hedgehog.

Included among the small molecules covered by this patent is CUR-61414, a compound that is under development by CURIS as a treatment for basal cell carcinoma, the most common form of cancer in the United States.

A recent report in The Proceedings of the National Academy of Sciences has shown that CUR-61414 can selectively kill tumor cells while not harming adjacent normal cells in two models of basal cell carcinoma. This selectivity contrasts with more traditional cancer treatments that often kill both cancer cells and normal cells.

"The ability to selectively kill cancer cells while leaving healthy cells intact represents the next generation of cancer treatments that are in development," stated Dr. Lee Rubin, CURIS` Chief Scientific Officer. "We believe that methods of inhibiting the Hedgehog signaling pathway represents a significant addition to this new therapeutic approach in cancer treatment."

"In addition to basal cell carcinoma, the Hedgehog signaling pathway has been implicated in the progression of several cancers, including small cell lung cancer, medulloblastoma, and others," said Daniel Passeri, CURIS` President and Chief Executive Officer. "CURIS is currently evaluating other cancer types to determine those tumors that also may be responsive to Hedgehog signaling pathway inhibition."

[benefactor [KommA]]

Der Money Flow sieht nicht gerade vielversprechend aus.